Literature DB >> 16166437

Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors.

Florian Haller1, Bastian Gunawan, Anja von Heydebreck, Stefanie Schwager, Hans-Jürgen Schulten, Judith Wolf-Salgó, Claus Langer, Giuliano Ramadori, Holger Sültmann, László Füzesi.   

Abstract

PURPOSE: The aim of the current study was to examine the prognostic relevance of the CDKN2A tumor suppressor pathway in gastrointestinal stromal tumors (GIST). EXPERIMENTAL
DESIGN: We determined the mRNA expression of p1(INK4A), p14(ARF), CDK4, RB1, MDM2, TP53, and E2F1 by quantitative reverse transcription-PCR in 38 cases of GISTs and correlated the findings with clinicopathologic factors, including mutation analysis of KIT and PDGFRA.
RESULTS: The k-means cluster analysis yielded three prognostic subgroups of GISTs with distinct mRNA expression patterns of the CDKN2A pathway. GISTs with low mRNA expression of the CDKN2A transcripts p16(INK4A) and p14(ARF) but high mRNA expression of CDK4, RB1, MDM2, TP53, and E2F1 were associated with aggressive clinical behavior and unfavorable prognosis, whereas GISTs with a low mRNA expression of CDK4, RB1, MDM2, TP53, and E2F1 were not. GISTs with a moderate to high mRNA expression of all examined genes also seemed to be associated with unfavorable prognosis. Regarding mutation analysis, we found significant differences in the KIT/PDGFRA genotype among the three clusters. Univariate analysis revealed high expression of E2F1 to be associated with mitotic count, proliferation rate, KIT mutation, and aggressive clinical behavior. These findings on mRNA level could be confirmed by immunohistochemistry.
CONCLUSION: Our findings implicate differential regulation schemes of the CDKN2A tumor suppressor pathway converging to up-regulation of E2F1 as the critical link to increased cell proliferation and adverse prognosis of GISTs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166437     DOI: 10.1158/1078-0432.CCR-05-0329

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

1.  [Multilayer analysis of signal transduction and cell cycle control in GIST. Identifying new interaction partners with differential regulation].

Authors:  F Haller; D J Zhang; C Löbke; A von Heydebreck; U Korf; L Füzesi; O Sahin
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

2.  [Molecular biological evaluation of prognostic parameters in GIST. Development of an integrative model of tumor progression].

Authors:  F Haller
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

3.  Loss of chromosome 9p21 and decreased p16 expression correlate with malignant gastrointestinal stromal tumor.

Authors:  Yun Zhang; Hui Cao; Ming Wang; Wen-Yi Zhao; Zhi-Yong Shen; Dan-Ping Shen; Xing-Zhi Ni; Zhi-Yong Wu; Yan-Ying Shen; Yan-Yan Song
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

4.  Improved detection of KIT exon 11 duplications in formalin-fixed, paraffin-embedded gastrointestinal stromal tumors.

Authors:  Jerzy Lasota; Bartosz Wasag; Sonja E Steigen; Janusz Limon; Markku Miettinen
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

5.  Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor.

Authors:  Shan Zeng; Adrian M Seifert; Jennifer Q Zhang; Michael J Cavnar; Teresa S Kim; Vinod P Balachandran; Juan A Santamaria-Barria; Noah A Cohen; Michael J Beckman; Benjamin D Medina; Ferdinand Rossi; Megan H Crawley; Jennifer K Loo; Joanna H Maltbaek; Peter Besmer; Cristina R Antonescu; Ronald P DeMatteo
Journal:  Mol Cancer Ther       Date:  2017-06-13       Impact factor: 6.261

Review 6.  An update on molecular genetics of gastrointestinal stromal tumours.

Authors:  L Tornillo; L M Terracciano
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

7.  Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).

Authors:  Silke Cameron; Marieke Gieselmann; Martina Blaschke; Giuliano Ramadori; Laszlo Füzesi
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

8.  p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome.

Authors:  Michael Schmieder; Sebastian Wolf; Bettina Danner; Susanne Stoehr; Markus S Juchems; Peter Wuerl; Doris Henne-Bruns; Uwe Knippschild; Cornelia Hasel; Klaus Kramer
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

Review 9.  Genetic aberrations of gastrointestinal stromal tumors.

Authors:  Jilong Yang; Xiaoling Du; Alexander J F Lazar; Raphael Pollock; Kelly Hunt; Kexin Chen; Xishan Hao; Jonathan Trent; Wei Zhang
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

10.  Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.

Authors:  Carlos A Torres-Cabala; Wei-Lien Wang; Jonathan Trent; Dan Yang; Su Chen; John Galbincea; Kevin B Kim; Scott Woodman; Michael Davies; Jose A Plaza; J W Nash; Victor G Prieto; Alexander J Lazar; Doina Ivan
Journal:  Mod Pathol       Date:  2009-08-28       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.